Advertisement

Vitiligo pp 81-91 | Cite as

Clinically Inflammatory Vitiligo and Rare Variants

  • Alain TaïebEmail author
  • Khaled Ezzedine
  • Julien Seneschal
  • Ratnam Attili
Chapter

Abstract

A particular form of vitiligo of clinically inflammatory vitiligo has been reported as “inflammatory vitiligo with raised borders” or marginal vitiligo and is associated with lichenoid infiltrates in the margins of progressing lesions. In pigmented progressing borders of common vitiligo/NSV and SV, similar features of lesser intensity have been demonstrated suggesting that most subtypes of vitiligo belong to the spectrum of a clinically silent chronic inflammatory skin disorder responsible for melanocyte loss. Clinically inflammatory vitiligo (CIV) has been sometimes associated with infectious or inflammatory diseases. Other rare variants considered in this chapter include follicular vitiligo, vitiligo/leukoderma guttata, and hypopigmented vitiligo/vitiligo minor. For both CIV and hypopigmented vitiligo, biopsies (sometimes repeated) are needed to establish a firm diagnosis, in particular to exclude cutaneous T-cell lymphoma, a major differential diagnosis.

References

  1. 1.
    Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Buckley W, Lobitz W. Vitiligo with raised inflammatory border. Arch Derm Syph. 1953;67:316–20.CrossRefGoogle Scholar
  3. 3.
    Garb J, Wise F. Vitiligo with raised borders. Arch Derm Syphilol. 1948;58:149–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Wise F. Leukoderma with inflammatory borders. Arch Derm Syph. 1942;45:218–9.CrossRefGoogle Scholar
  5. 5.
    Duvic M, Rapini R, Hoots WK, et al. Human immunodeficiency virus-associated vitiligo: expression of autoimmunity with immunodeficiency? J Am Acad Dermatol. 1987;17:656–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Grandhe NP, Dogra S, Kumar B. Spontaneous repigmentation of vitiligo in an untreated HIV-positive patient. J Eur Acad Dermatol Venereol. 2006;20:234–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Niamba P, Traoré A, Taieb A. Vitiligo sur peau noire associée au VIH et repigmentation lors du traitement antiretroviral. Ann Dermatol Venereol. 2007;134:272–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Tsuboi H, Yonemoto K, Katsuoka K. Vitiligo with inflammatory raised borders with hepatitis C virus infection. J Dermatol. 2006;33:577–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Weisberg EL, Le LQ, Cohen JB. A case of simultaneously occurring lichen sclerosus and segmental vitiligo: connecting the underlying autoimmune pathogenesis. Int J Dermatol. 2008;47:1053–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Sugita K, Izu K, Tokura Y. Vitiligo with inflammatory raised borders, associated with atopic dermatitis. Clin Exp Dermatol. 2006;31:80–2.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsuruta D, Hamada T, Teramae H, et al. Inflammatory vitiligo in Vogt-Koyanagi-Harada disease. J Am Acad Dermatol. 2001;44:129–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Wong SS, Ng SK, Lee HM. Vogt-Koyanagi-Harada Disease: extensive vitiligo with prodromal generalized erythroderma. Dermatology. 1999;198:65–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Gunasekera N, Murphy GF, Sheth VM. Repigmentation of extensive inflammatory vitiligo with raised borders using early and aggressive treatment. Dermatology. 2015;230(1):11–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Michaëlsson G. Vitiligo with raised borders. Report of two cases. Acta Derm Venereol. 1968;48:158–61.PubMedGoogle Scholar
  15. 15.
    Ortonne JP, Baran R, Civatte J. Vitiligo with an inflammatory border. A propos of 2 cases with review of the literature (18 cases). Ann Dermatol Venereol. 1979;106:613–5.PubMedGoogle Scholar
  16. 16.
    Petit T, Cribier B, Bagot M, Wechsler J. Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides. Eur J Dermatol. 2003;17:410–2.Google Scholar
  17. 17.
    Swick BL, Walling HW. Depigmented patches with an annular inflammatory border. Clin Exp Dermatol. 2008;33:671–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Shin J, Lee JS, Kim MR, Kim do Y, Hann SK, Oh SH. New suggestive clue to the mechanism of vitiligo: inflammatory vitiligo showing prominent leukocytoclasis at the erythematous rim. J Dermatol. 2013;40(6):488–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Trikha R, McCowan N, Brodell R. Marginal vitiligo: an unusual depigmenting disorder. Dermatol Online J. 2014;21(3):pii: 13030.Google Scholar
  20. 20.
    Yagi H, Tokura Y, Furukawa Y, Takigawa M. Vitiligo with raised inflammatory borders: involvement of T cell immunity and keratinocytes expressing MHC class II and ICAM-1 molecules. Eur J Dermatol. 1997;7:19–22.Google Scholar
  21. 21.
    Tanioka M, Takahashi K, Miyachi YI. Narrowband ultraviolet B phototherapy for inflammatory vitiligo with raised borders associated with Sjögren’s syndrome. Clin Exp Dermatol. 2009;34(3):418–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Annessi G, Paradisi M, Angelo C, et al. Annular lichenoid dermatitis of youth. J Am Acad Dermatol. 2003;49:1029–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Attili VR, Attili SK. Lichenoid inflammation in vitiligo-a clinical and histopathologic review of 210 cases. Int J Dermatol. 2008;47:663–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Hann SK, Park YK, Lee KG, et al. Epidermal changes in active vitiligo. J Dermatol. 1992;19:217–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Sharquie KE, Mehenna SH, Naji AA, Al-Azzawi H. Inflammatory changes in vitiligo: stage I and II depigmentation. Am J Dermatopathol. 2004;26:108–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Attili VR, Attili SK. Segmental and generalized vitiligo: both forms demonstrate inflammatory histopathological features and clinical mosaicism. Indian J Dermatol. 2013;58(6):433–8.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Ezzedine K, Amazan E, Seneschal J, Cario-André M, Léauté-Labrèze C, Vergier B, Boralevi F, Taieb A. Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res. 2012a;25(4):527–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Ezzedine K, Amazan E, Séneschal J, Cario-André M, Léauté-Labrèze C, Vergier B, Boralevi F, Taieb A. Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res. 2012b;25:527–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Gan EY, Cario-André M, Pain C, Goussot JF, Taïeb A, Seneschal J, Ezzedine K. Follicular vitiligo: a report of 8 cases. J Am Acad Dermatol. 2016;74(6):1178–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Ezzedine K, Mahé A, van Geel N, Cardot-Leccia N, Gauthier Y, Descamps V, Al Issa A, Ly F, Chosidow O, Taïeb A, Passeron T. Hypochromic vitiligo: delineation of a new entity. Br J Dermatol. 2015;172(3):716–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Gameiro A, Gouveia M, Tellechea Ó, Moreno A. Childhood hypopigmented mycosis fungoides: a commonly delayed diagnosis. BMJ Case Rep. 2014;2014:pii: bcr2014208306.CrossRefGoogle Scholar
  32. 32.
    Ranawaka RR, Abeygunasekara PH, de Silva MV. Hypopigmented mycosis fungoides in type v skin: a report of 5 cases. Case Rep Dermatol Med. 2011;2011:190572.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Soro LA, Gust AJ, Purcell SM. Inflammatory vitiligo versus hypopigmented mycosis fungoides in a 58-year-old Indian female. Indian Dermatol Online J. 2013;4(4):321–5.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Tolkachjov SN, Comfere NI. Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo. J Drugs Dermatol. 2015;14(2):193–4.PubMedGoogle Scholar
  35. 35.
    Falabella R, Escobar CE, Carrascal E, Arroyave JA. Leukoderma punctata. J Am Acad Dermatol. 1988;18(3):485–94.PubMedCrossRefGoogle Scholar
  36. 36.
    Loquai C, Metze D, Nashan D, Luger TA, Böhm M. Confetti-like lesions with hyperkeratosis: a novel ultraviolet-induced hypomelanotic disorder? Br J Dermatol. 2005;153:190–3.PubMedCrossRefGoogle Scholar
  37. 37.
    Verma S, Joshi R. Amyloidosis cutis dyschromica: a rare reticulate pigmentary dermatosis. Indian J Dermatol. 2015;60:385–7.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Taïeb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 2012;25(1):9–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, McFann KK, Holland PJ, Fain PR, Dinarello CA, Spritz RA. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci. 2013;110(8):2952–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, Picardo M, Taieb A, Ezzedine K, Cario-André M. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol. 2014;170(4):816–23.PubMedCrossRefGoogle Scholar
  41. 41.
    Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013;5(174):174ra28.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alain Taïeb
    • 1
    Email author
  • Khaled Ezzedine
    • 1
  • Julien Seneschal
    • 1
  • Ratnam Attili
    • 2
  1. 1.Service de dermatologieHôspital St André, CHU de BordeauxBordeauxFrance
  2. 2.Visakha Institute of Skin and AllergyVisakhapatnamIndia

Personalised recommendations